Tagged with GI

Array Maria Cristina G. Coronel (‘Beng’), President of Pointwest Technologies, and colleagues Rhea Latoga and Ma. Lillibeth Daffon (‘Beth’), discuss the current high growth rate within the healthcare sector, why being both an IT and BPO company, Pointwest Technologies has an edge over companies that focus on BPO alone, and how…

partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…

Interface Biologics Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined IBI in 2008, what was your initial mandate upon arriving here? My initial mandate was to demonstrate commercial viability. Since…

GCB Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp. under your leadership? GBC was established in 1984. Government shareholders held 70 percent ownership, with the remaining 30 percent distributed…

APAC Region PAREXEL has been in Asia Pacific (APAC) since the company entered Japan in 1995. It chose Taiwan as its regional base of operations with the 2007 acquisition of APEX, a company you founded in 1999. Today, does Taiwan continue to make sense as PAREXEL’s APAC headquarters? We believe that it…

Government Regulation As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate need for better legislation in this area for the benefit of patients, and the misconceptions of treating Canada as a…

Government Regulation An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a company dedicated to bringing unique drugs into the country in the areas of women’s health, dermatology and urology.   What have been some of…

logistics     World Courier’s national operations manager in Canada covers the topics of moving to GxP standards, and the logistics challenges faced by being a logistics company in such a large country. What originally attracted you to the logistics business? I came into the business by accident, at that time…

Gilead Nordics As the blockbuster sales model fades, the rush is on for a new formula for growth, termed  ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable with high margins from protected pricing, more patient-friendly than patent-centric and with revenues coming from a deep reservoir of unmet medical need. How well…

Cedegim Colombia               The operations and sales managers of Cegedim Colombia discuss the impact of healthcare reform on the Colombian pharma market, partnering opportunities in the country, and the outlook for CRM in 2013 and beyond. Can you briefly summarize Cegedim Colombia’s scope of activities and…

Belgium Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout the years? Tom Heyman (TH): Janssen Pharmaceutica is all about innovation—developing, producing and providing innovative healthcare solutions for patients. When…

Novartis Belgium Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your way up the ladder. What attracted you to this industry and Novartis specifically? Prior to beginning my career as a…